Total Liabilities Summary of Novavax, Inc.

Novavax, Inc.'s latest annual total liabilities in 2023 was 2.51 Billion USD , down -13.08% from previous year.
Novavax, Inc.'s latest quarterly total liabilities in 2024 Q2 was 2.25 Billion USD , up 1.34% from previous quarter.
Novavax, Inc. reported annual total liabilities of 2.89 Billion USD in 2022, down -1.22% from previous year.
Novavax, Inc. reported annual total liabilities of 2.92 Billion USD in 2021, up 206.55% from previous year.
Novavax, Inc. reported quarterly total liabilities of 2.25 Billion USD for 2024 Q2, up 1.34% from previous quarter.
Novavax, Inc. reported quarterly total liabilities of 2.43 Billion USD for 2023 Q2, up 0.05% from previous quarter.

Annual Total Liabilities Chart of Novavax, Inc. (2023 - 1996)

Historical Annual Total Liabilities of Novavax, Inc. (2023 - 1996)

Year	Total Liabilities	Total Liabilities Growth
2023	2.51 Billion USD	-13.08%
2022	2.89 Billion USD	-1.22%
2021	2.92 Billion USD	206.55%
2020	955.27 Million USD	166.11%
2019	358.97 Million USD	-4.51%
2018	375.91 Million USD	-7.0%
2017	404.22 Million USD	1.09%
2016	399.84 Million USD	328.24%
2015	93.36 Million USD	101.3%
2014	46.38 Million USD	41.83%
2013	32.7 Million USD	47.94%
2012	22.1 Million USD	73.69%
2011	12.72 Million USD	-19.42%
2010	15.79 Million USD	41.78%
2009	11.14 Million USD	-64.22%
2008	31.13 Million USD	10.31%
2007	28.22 Million USD	1.26%
2006	27.87 Million USD	-19.74%
2005	34.73 Million USD	-22.33%
2004	44.71 Million USD	-7.27%
2003	48.21 Million USD	-2.46%
2002	49.43 Million USD	24.76%
2001	39.62 Million USD	60.38%
2000	24.7 Million USD	1353.24%
1999	1.7 Million USD	112.5%
1998	800 Thousand USD	166.67%
1997	300 Thousand USD	-50.0%
1996	600 Thousand USD	0.0%

Year	Total Liabilities	Total Liabilities Growth
2024 Q1	2.22 Billion USD	-11.68%
2024 Q2	2.25 Billion USD	1.34%
2023 Q2	2.43 Billion USD	0.05%
2023 Q4	2.51 Billion USD	7.66%
2023 Q3	2.33 Billion USD	-4.27%
2023 Q1	2.43 Billion USD	-15.71%
2023 FY	2.51 Billion USD	-13.08%
2022 FY	2.89 Billion USD	-1.22%
2022 Q4	2.89 Billion USD	2.09%
2022 Q3	2.83 Billion USD	-6.79%
2022 Q1	2.76 Billion USD	-5.43%
2022 Q2	3.03 Billion USD	9.76%
2021 Q1	1.56 Billion USD	64.27%
2021 Q2	2 Billion USD	27.71%
2021 FY	2.92 Billion USD	206.55%
2021 Q4	2.92 Billion USD	39.14%
2021 Q3	2.1 Billion USD	5.02%
2020 Q3	837.58 Million USD	12.02%
2020 FY	955.27 Million USD	166.11%
2020 Q2	747.7 Million USD	112.39%
2020 Q4	955.27 Million USD	14.05%
2020 Q1	352.03 Million USD	-1.93%
2019 Q4	358.97 Million USD	1.22%
2019 FY	358.97 Million USD	-4.51%
2019 Q2	374.88 Million USD	0.8%
2019 Q1	371.9 Million USD	-1.07%
2019 Q3	354.64 Million USD	-5.4%
2018 Q3	377.15 Million USD	0.98%
2018 FY	375.91 Million USD	-7.0%
2018 Q1	375.43 Million USD	-7.12%
2018 Q2	373.51 Million USD	-0.51%
2018 Q4	375.91 Million USD	-0.33%
2017 Q2	414.76 Million USD	6.19%
2017 Q1	390.6 Million USD	-2.31%
2017 FY	404.22 Million USD	1.09%
2017 Q4	404.22 Million USD	-0.98%
2017 Q3	408.22 Million USD	-1.58%
2016 Q4	399.84 Million USD	-2.44%
2016 Q1	407.07 Million USD	335.98%
2016 Q2	414.88 Million USD	1.92%
2016 Q3	409.84 Million USD	-1.22%
2016 FY	399.84 Million USD	328.24%
2015 Q3	37.61 Million USD	1.41%
2015 FY	93.36 Million USD	101.3%
2015 Q1	39.13 Million USD	-15.63%
2015 Q4	93.36 Million USD	148.2%
2015 Q2	37.09 Million USD	-5.21%
2014 Q1	27.53 Million USD	-15.79%
2014 Q3	30.86 Million USD	2.0%
2014 Q4	46.38 Million USD	50.29%
2014 Q2	30.26 Million USD	9.88%
2014 FY	46.38 Million USD	41.83%
2013 Q2	23.69 Million USD	12.09%
2013 Q4	32.7 Million USD	14.75%
2013 Q3	28.5 Million USD	20.29%
2013 Q1	21.13 Million USD	-4.38%
2013 FY	32.7 Million USD	47.94%
2012 Q3	19.17 Million USD	20.58%
2012 FY	22.1 Million USD	73.69%
2012 Q1	14.31 Million USD	12.46%
2012 Q2	15.89 Million USD	11.07%
2012 Q4	22.1 Million USD	15.31%
2011 Q3	12.48 Million USD	-4.49%
2011 Q2	13.07 Million USD	-21.27%
2011 Q1	16.6 Million USD	5.15%
2011 FY	12.72 Million USD	-19.42%
2011 Q4	12.72 Million USD	1.91%
2010 Q1	12.23 Million USD	9.86%
2010 FY	15.79 Million USD	41.78%
2010 Q3	12.32 Million USD	7.87%
2010 Q4	15.79 Million USD	28.19%
2010 Q2	11.42 Million USD	-6.67%
2009 FY	11.14 Million USD	-64.22%
2009 Q2	13.5 Million USD	-55.25%
2009 Q3	8.86 Million USD	-34.35%
2009 Q4	11.14 Million USD	25.69%
2009 Q1	30.16 Million USD	-3.11%
2008 Q3	33.38 Million USD	-0.5%
2008 Q2	33.55 Million USD	10.29%
2008 Q1	30.42 Million USD	7.79%
2008 FY	31.13 Million USD	10.31%
2008 Q4	31.13 Million USD	-6.74%
2007 Q3	27.82 Million USD	0.15%
2007 FY	28.22 Million USD	1.26%
2007 Q1	28.27 Million USD	1.44%
2007 Q2	27.78 Million USD	-1.76%
2007 Q4	28.22 Million USD	1.45%
2006 Q2	26.74 Million USD	1.59%
2006 Q1	26.32 Million USD	-24.2%
2006 FY	27.87 Million USD	-19.74%
2006 Q4	27.87 Million USD	6.23%
2006 Q3	26.24 Million USD	-1.88%
2005 Q4	34.73 Million USD	-14.55%
2005 FY	34.73 Million USD	-22.33%
2005 Q3	40.64 Million USD	-2.31%
2005 Q1	42.18 Million USD	-5.66%
2005 Q2	41.6 Million USD	-1.37%
2004 Q4	44.71 Million USD	1.48%
2004 Q3	44.05 Million USD	-14.08%
2004 Q2	51.27 Million USD	6.72%
2004 Q1	48.05 Million USD	-0.34%
2004 FY	44.71 Million USD	-7.27%
2003 FY	48.21 Million USD	-2.46%
2003 Q4	48.21 Million USD	-1.06%
2003 Q3	48.73 Million USD	1.98%
2003 Q1	48.34 Million USD	-2.21%
2003 Q2	47.78 Million USD	-1.15%
2002 Q2	50.27 Million USD	26.12%
2002 Q3	49.19 Million USD	-2.15%
2002 Q4	49.43 Million USD	0.49%
2002 FY	49.43 Million USD	24.76%
2002 Q1	39.86 Million USD	0.6%
2001 Q2	28.1 Million USD	16.82%
2001 FY	39.62 Million USD	60.38%
2001 Q1	24.05 Million USD	-2.62%
2001 Q4	39.62 Million USD	2.03%
2001 Q3	38.83 Million USD	38.18%
2000 Q2	1.71 Million USD	21.91%
2000 Q1	1.4 Million USD	-17.29%
2000 Q3	2.02 Million USD	18.26%
2000 Q4	24.7 Million USD	1118.8%
2000 FY	24.7 Million USD	1353.24%
1999 Q4	1.7 Million USD	70.0%
1999 Q2	300 Thousand USD	-66.67%
1999 Q1	900 Thousand USD	12.5%
1999 Q3	1 Million USD	233.33%
1999 FY	1.7 Million USD	112.5%
1998 Q1	300 Thousand USD	0.0%
1998 Q4	800 Thousand USD	300.0%
1998 Q2	300 Thousand USD	0.0%
1998 FY	800 Thousand USD	166.67%
1998 Q3	200 Thousand USD	-33.33%
1997 Q4	300 Thousand USD	50.0%
1997 FY	300 Thousand USD	-50.0%
1997 Q2	500 Thousand USD	25.0%
1997 Q1	400 Thousand USD	-33.33%
1997 Q3	200 Thousand USD	-60.0%
1996 Q2	500 Thousand USD	0.0%
1996 Q4	600 Thousand USD	50.0%
1996 Q3	400 Thousand USD	-20.0%
1996 Q1	500 Thousand USD	0.0%
1996 FY	600 Thousand USD	0.0%

Peer Total Liabilities Comparison of Novavax, Inc.

Name	Total Liabilities	Total Liabilities Difference
BioNTech SE	2.76 Billion EUR	8.911%
CureVac N.V.	271.53 Million EUR	-826.012%
Biotest Aktiengesellschaft	945.4 Million EUR	-165.963%
Biotest Aktiengesellschaft	945.4 Million EUR	-165.963%
BRAIN Biotech AG	47.92 Million EUR	-5146.785%
Formycon AG	387.61 Million EUR	-548.696%
Heidelberg Pharma AG	21.01 Million EUR	-11865.873%
Medigene AG	10.65 Million EUR	-23509.549%

Global Stocks Search

Novavax, Inc. (NVV1.F)

Total Liabilities Summary of Novavax, Inc.

Annual Total Liabilities Chart of Novavax, Inc. (2023 - 1996)

Historical Annual Total Liabilities of Novavax, Inc. (2023 - 1996)

Peer Total Liabilities Comparison of Novavax, Inc.